Educational content only. Not medical advice. The content creators are not doctors or medical professionals. Consult your healthcare provider before taking any action.
Quick answer
In the Phase 3 TRIUMPH-1 trial reported in May 2026, retatrutide produced mean weight loss of 19.0% (4 mg), 25.9% (9 mg), and 28.3% (12 mg) over 80 weeks, with about 45% of 12 mg users losing 30%+. Retatrutide remains investigational and is not FDA-approved.
The headline retatrutide weight loss results from 2026 come from the Phase 3 TRIUMPH-1 trial: adults on the 12 mg dose lost a mean of 28.3% of body weight at 80 weeks. Retatrutide is an investigational triple-receptor agonist (GIP, GLP-1, and glucagon) studied for obesity. It is not FDA-approved and remains a clinical-trial agent.
Retatrutide at a glance
- Class: investigational triple-hormone-receptor agonist (GIP / GLP-1 / glucagon); also called LY3437943
- Headline 2026 result: mean 28.3% body-weight reduction at 80 weeks (12 mg, TRIUMPH-1 topline)
- Lower doses (TRIUMPH-1): 19.0% at 4 mg; 25.9% at 9 mg
- Route / frequency: once-weekly subcutaneous injection (in trials)
- Best-studied for: obesity/overweight; also studied for liver fat (MASLD)
- FDA status: not approved; investigational. Not eligible for 503A or 503B compounding
- Manufacturer / status: Eli Lilly; Phase 3 program ongoing in 2026
What is retatrutide?
Retatrutide (development code LY3437943) is an investigational, once-weekly injectable molecule that activates three metabolic hormone receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor (Jastreboff et al., 2023, N Engl J Med). Because it engages three pathways, it is often described as a "triple agonist" or "triple-G" agonist — a step beyond single-agonist GLP-1 drugs like semaglutide and the dual GIP/GLP-1 agonist tirzepatide.
It is a peptide-based therapeutic developed by Eli Lilly. As of June 2026 it is an experimental drug being evaluated in late-stage clinical trials; it is not a marketed product. For background on how this class works, see our GLP-1 peptides explained primer.
How does retatrutide work?
The rationale for adding glucagon-receptor activity to the GIP/GLP-1 combination is that glucagon agonism may increase energy expenditure and influence liver-fat metabolism, while GLP-1 and GIP agonism reduce appetite and improve glucose handling (Jastreboff et al., 2023, N Engl J Med). The combined effect, as observed in trials, is appetite suppression plus a metabolic-rate component.
Evidence for the liver-fat pathway comes from a separate randomized Phase 2a study in people with metabolic dysfunction-associated steatotic liver disease (MASLD), where retatrutide was associated with large reductions in liver fat content versus placebo (Sanyal et al., 2024, Nat Med). These are research findings in defined trial populations, not a treatment claim — retatrutide is not approved for any indication. Consult your healthcare provider before considering any peptide protocol.
What were the retatrutide weight loss results in 2026?
The headline 2026 data come from TRIUMPH-1, a Phase 3, randomized, double-blind, placebo-controlled trial in adults with obesity or overweight (and at least one weight-related condition) but without type 2 diabetes (ClinicalTrials.gov, NCT05929066). Eli Lilly reported topline results on May 21, 2026 (Eli Lilly press release, 2026).
TRIUMPH-1 mean body-weight reduction at 80 weeks (topline):
| Dose | Mean weight reduction | Approx. pounds lost |
|---|---|---|
| Retatrutide 4 mg | 19.0% | ~47.2 lb |
| Retatrutide 9 mg | 25.9% | ~64.4 lb |
| Retatrutide 12 mg | 28.3% | ~70.3 lb |
According to Lilly's announcement, 45.3% of participants on the 12 mg dose achieved at least 30% body-weight reduction (Eli Lilly press release, 2026). The trial randomized roughly 2,335 participants and ran approximately 80 weeks on treatment, with an optional extension (ClinicalTrials.gov, NCT05929066). Lilly also referenced an extension cohort in which the 12 mg group reached approximately 30.3% mean reduction over a longer period; treat any single extension figure as preliminary until peer-reviewed publication [VERIFY: 30.3% extension figure pending full publication].
These percentages are in the range of, and at the top doses approach, results seen with bariatric surgery — which is why the topline drew attention. Note that these are company-reported topline numbers; the full, peer-reviewed dataset was expected to be presented at scientific meetings (the American Diabetes Association 2026 Scientific Sessions, June 5–8) with journal publication to follow [VERIFY: peer-reviewed TRIUMPH-1 publication and conference presentation].
How do the 2026 results compare to the earlier Phase 2 data?
The 2026 Phase 3 topline is consistent with — and extends — retatrutide's Phase 2 obesity trial. In that 48-week Phase 2 study of 338 adults with obesity, the least-squares mean change in body weight was −24.2% in the 12 mg group versus −2.1% with placebo (Jastreboff et al., 2023, N Engl J Med). Lower-dose groups showed −8.7% (1 mg), −17.1% (combined 4 mg), and −22.8% (combined 8 mg).
The Phase 2 results were notable because weight loss had not clearly plateaued by week 48, suggesting room for further reduction with longer dosing — a hypothesis the longer 80-week Phase 3 duration appears to support. For how retatrutide stacks up against the dual agonist tirzepatide, see our tirzepatide vs. retatrutide comparison.
What are the side effects and safety considerations?
Across the Phase 2 and Phase 3 programs, the most common adverse events were gastrointestinal — nausea, vomiting, diarrhea, and constipation — generally mild to moderate and concentrated during dose escalation (Jastreboff et al., 2023, N Engl J Med). This profile is typical of incretin-based drugs.
In the TRIUMPH-1 topline, treatment discontinuation due to adverse events rose with dose: approximately 4.1% at 4 mg, 6.9% at 9 mg, and 11.3% at 12 mg, versus 4.9% on placebo (Eli Lilly press release, 2026). The higher discontinuation rate at the top dose is a meaningful tolerability signal that analysts flagged and that full trial data will clarify. Earlier-phase work also noted dose-dependent increases in heart rate, a known effect of this drug class that the full Phase 3 safety dataset is expected to characterize further [VERIFY: heart-rate findings in TRIUMPH-1 full dataset].
Because retatrutide is investigational, its long-term safety, drug interactions, and effects in special populations are not fully established. Anyone considering any incretin or peptide therapy should do so only under medical supervision. Consult your healthcare provider before starting any peptide protocol.
Is retatrutide FDA-approved or legal to buy in 2026?
No. As of June 2026, retatrutide is not FDA-approved for any use; it is an investigational drug still completing Phase 3 trials, with a regulatory filing and possible approval generally projected for the 2027–2028 window [VERIFY: specific approval-timeline projection]. It is not available by prescription as a finished product.
Critically, retatrutide is not eligible for legal compounding. In 2025, the FDA issued warning letters stating that drug products compounded using retatrutide are not eligible for the exemptions under section 503A — because retatrutide is not the subject of an applicable USP/NF monograph, is not a component of an FDA-approved drug, and does not appear on the 503A bulks list — and are likewise not eligible under section 503B, because retatrutide is not on the 503B bulks list (FDA Warning Letter, 2025). In plain terms: "research" or compounded retatrutide sold online is unapproved, and the FDA has actively warned sellers.
This is separate from the FDA's broader 2026 peptide review. The Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 2026 is slated to evaluate certain research peptides (such as BPC-157 and others) for the compounding bulks lists; based on available agendas, retatrutide is a Phase 3 pharmaceutical and is not part of that peptide-bulks review (FDA PCAC, 2026) [VERIFY: final PCAC July 2026 agenda]. For the wider picture, see our peptide legality and FDA status overview. Legal status varies by jurisdiction; consult a lawyer for binding advice.
Frequently asked questions
Q: How much weight did people lose on retatrutide in the 2026 TRIUMPH trial? A: In Eli Lilly's TRIUMPH-1 Phase 3 topline (reported May 2026), adults without type 2 diabetes lost a mean of 19.0% of body weight on 4 mg, 25.9% on 9 mg, and 28.3% on 12 mg over about 80 weeks; roughly 45% of those on 12 mg lost at least 30% of their body weight (Eli Lilly press release, 2026). These are company-reported topline figures pending peer-reviewed publication. Individual results vary, and retatrutide is not approved or available by prescription.
Q: Is retatrutide better than Ozempic or Mounjaro? A: Cross-trial comparisons are imprecise, but retatrutide's reported weight-loss percentages are numerically higher than published results for semaglutide (Ozempic/Wegovy) and at the top dose exceed many tirzepatide (Mounjaro/Zepbound) figures. However, retatrutide is still investigational, head-to-head data are limited, and tolerability differs by dose. Discuss any medication choice with your healthcare provider.
Q: Can I buy retatrutide legally in 2026? A: No FDA-approved retatrutide product exists, and it is not eligible for 503A or 503B compounding — the FDA issued warning letters to sellers in 2025 (FDA Warning Letter, 2025). Products marketed online as retatrutide are unapproved and unverified. Legitimate access is generally limited to enrollment in an authorized clinical trial. Consult a licensed provider; legal status varies by jurisdiction.
Q: When will retatrutide be approved by the FDA? A: There is no approval as of June 2026. Retatrutide is completing its Phase 3 TRIUMPH program, and industry projections commonly cite a possible approval in roughly 2027–2028, depending on filing timing and FDA review [VERIFY: approval-timeline projection]. Timelines for investigational drugs frequently shift.
Q: What are the main side effects of retatrutide? A: The most common adverse events reported in trials are gastrointestinal — nausea, vomiting, diarrhea, and constipation — usually mild to moderate and most frequent during dose escalation (Jastreboff et al., 2023, N Engl J Med). Discontinuation due to adverse events rose with dose in TRIUMPH-1 (about 11.3% at 12 mg). Dose-dependent heart-rate increases have also been noted for this drug class. Long-term safety is not yet established. Consult your healthcare provider.
Q: How is retatrutide different from tirzepatide? A: Tirzepatide is a dual agonist (GIP and GLP-1 receptors). Retatrutide adds a third target — the glucagon receptor — making it a triple agonist; the added glucagon activity is thought to contribute to energy expenditure and liver-fat effects (Jastreboff et al., 2023, N Engl J Med; Sanyal et al., 2024, Nat Med). Tirzepatide is FDA-approved; retatrutide is not.
Q: Was retatrutide studied for anything besides weight loss? A: Yes. Beyond obesity, retatrutide was evaluated in a randomized Phase 2a trial in metabolic dysfunction-associated steatotic liver disease (MASLD), where it was associated with substantial reductions in liver fat content versus placebo (Sanyal et al., 2024, Nat Med). The broader Phase 3 program also includes studies in type 2 diabetes and cardiovascular/kidney outcomes. These are research findings, not approved indications.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315. DOI: 10.1056/NEJMoa2301972.
- Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. PMID: 38858523. DOI: 10.1038/s41591-024-03018-2.
- ClinicalTrials.gov. A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (TRIUMPH-1). Identifier: NCT05929066. U.S. National Library of Medicine.
- Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (topline TRIUMPH-1 results). Press release, May 21, 2026. Available via PR Newswire.
- U.S. Food and Drug Administration. Warning Letter: GLP-1 Solution (715883), September 9, 2025 — retatrutide not eligible for 503A or 503B compounding exemptions. FDA.gov.
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) meeting, July 2026 — review of nominated bulk drug substances for use in compounding. FDA.gov / Federal Register.
Written By
Editorial team. We cite published research; we are not licensed clinicians and content is not medically reviewed.
Medical Disclaimer
The information on this website is for educational purposes only and is not medical advice. The content creators are not doctors or medical professionals. This content should not be used to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare provider before starting any new supplement, medication, or health protocol. You assume all risks associated with using this information.